Alzheimer’s Disease/Dementia News

SAN DIEGO – People should increase their exercise to reduce the risk of dementia or slow its progression, said a lecturer at the Alzheimer’s Association International Conference.

Alzamend Neuro has submitted an investigational new drug application to the FDA for its Alzheimer’s immunotherapeutic product, ALZN002, according to a company press release.

Corium Inc. announced that Adlarity transdermal treatment is available to prescribe in the U.S. for patients with Alzheimer’s.

SAN DIEGO – One compound from Annovis Bio is showing success in phase 2 clinical trials for both Alzheimer’s disease and Parkinsons’ disease, a company executive said at the Alzheimer’s Association International Conference.

Higher levels of the inflammatory marker C-reactive protein predicted lower reported cognitive function among older breast cancer survivors, according to study results published in Journal of Clinical Oncology.

The NIH has awarded a $10.7 million 5-year renewal grant to Cleveland Clinic to expand a national research consortium focused on improving the diagnosis and treatments for dementia with Lewy bodies.

Researchers identified a correlation between eGFR and urine albumin-creatinine ratio with structural brain damage across various regions of etiology, according to data published in the American Journal of Kidney Diseases.

LAS VEGAS — To slow or stave off symptoms relating to Alzheimer’s disease and dementia, individuals should make healthy habits a priority early in life, according to a presenter at BRAINWeek 2022.

Pharmaceutical companies Biogen and Eisai announced results from a phase 3 trial that demonstrated treatment with lecanemab reduced cognitive decline by 27% after 18 months compared with placebo.

Multimorbidity was associated with a 63% increased risk for incident dementia, with the greatest risk linked to hypertension and diabetes, researchers reported in JAMA Network Open.